[
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of February 15",
    "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. The monthly compilation can be overwhelming -- read the weekly breakdown here.",
    "url": "https://finnhub.io/api/news?id=2e832e1e5fa61c3b6f60ceded0e1c936f98a15379c8005a027a9ac04d1556a4d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771007615,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of February 15",
      "id": 139090956,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. The monthly compilation can be overwhelming -- read the weekly breakdown here.",
      "url": "https://finnhub.io/api/news?id=2e832e1e5fa61c3b6f60ceded0e1c936f98a15379c8005a027a9ac04d1556a4d"
    }
  },
  {
    "ts": null,
    "headline": "A Look At Quest Diagnostics (DGX) Valuation After Strong Results, 2026 Outlook, Buybacks And New Myeloma Test",
    "summary": "Quest Diagnostics (DGX) just paired a strong fourth quarter and full year 2025 with a confident 2026 outlook, a higher dividend, expanded buybacks, and new high value tests such as its myeloma MRD blood assay. See our latest analysis for Quest Diagnostics. The recent earnings beat, higher dividend, expanded buybacks, and new myeloma MRD test have arrived alongside a strong run in the shares, with a 30 day share price return of 14.95% and a 1 year total shareholder return of 24.88%. This...",
    "url": "https://finnhub.io/api/news?id=b0f17fd541b4cb52af7255d63c84116993c2384f4897b87a0b5e5e01b25369c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770984753,
      "headline": "A Look At Quest Diagnostics (DGX) Valuation After Strong Results, 2026 Outlook, Buybacks And New Myeloma Test",
      "id": 139081563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (DGX) just paired a strong fourth quarter and full year 2025 with a confident 2026 outlook, a higher dividend, expanded buybacks, and new high value tests such as its myeloma MRD blood assay. See our latest analysis for Quest Diagnostics. The recent earnings beat, higher dividend, expanded buybacks, and new myeloma MRD test have arrived alongside a strong run in the shares, with a 30 day share price return of 14.95% and a 1 year total shareholder return of 24.88%. This...",
      "url": "https://finnhub.io/api/news?id=b0f17fd541b4cb52af7255d63c84116993c2384f4897b87a0b5e5e01b25369c9"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.86",
    "summary": "The board of Quest Diagnostics Incorporated ( NYSE:DGX ) has announced that it will be paying its dividend of $0.86 on...",
    "url": "https://finnhub.io/api/news?id=1fff4f88457a3524a6a24768eb00aa77ffa8865b20980a22dfd805b65ce0888d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770981526,
      "headline": "Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.86",
      "id": 139079856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "The board of Quest Diagnostics Incorporated ( NYSE:DGX ) has announced that it will be paying its dividend of $0.86 on...",
      "url": "https://finnhub.io/api/news?id=1fff4f88457a3524a6a24768eb00aa77ffa8865b20980a22dfd805b65ce0888d"
    }
  }
]